MedPath

Cholesterol Metabolites Analysis in Human Thyroid and Iodine Resistance

Completed
Conditions
Thyroid Cancer
Registration Number
NCT04821336
Lead Sponsor
Institut Claudius Regaud
Brief Summary

The study team previously shown that a cholesterol metabolite, dendrogenin A (DDA) differentiates anaplastic thyroid cancer cell lines and that its mRNA expression is diminished in human radioiodine refractory thyroid cancer samples. The team aim to quantify via mass spectrometry and immunohistochemistry DDA and other cholesterol metabolites in thyroid cancer versus healthy thyroid tissue human samples.

Detailed Description

Retrospective study to analyze tissue samples of patients after thyroid surgery at Claudius Regaud Institute Toulouse, France, for thyroid cancer or thyroid aggressive lymphoma or benign thyroid pathology or other head\&neck pathology necessitating total thyroidectomy despite normal thyroid.

Analysis focused on cholesterol metabolites quatification by mass spectrometry in liquid and gas phase.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
30
Inclusion Criteria
  • Patients who have undergone surgery at Institut Claudius Regaud for thyroid or laryngeal cancer confirmed by histology.
  • Patients who have consented before surgery, for the use of participants samples for future researches.
Exclusion Criteria
  • None

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Rate of dendrogenin A (DDA) and 6-oxo-cholestane-3β,5α-diol (OCDO) in thyroid tissue (healthy or malignant)12 months after the beginning of the study

The measurement expressed in ng / g of thyroid tissue

Secondary Outcome Measures
NameTimeMethod
Presence of enzymes involved in dendrogenin A (DDA) and 6-oxo-cholestane-3β,5α-diol (OCDO) production12 months after the beginning of the study

intensity of signal in Liquid Chromatography-Mass Spectrometry

Number of enzymes involved in denrognenin A (DDA) and 6-oxo-cholestane-3β,5α-diol (OCDO) production12 months after the beginning of the study

Quantify by immunohistochemistry

Trial Locations

Locations (1)

Institut Claudius regaud IUCT Oncopole

🇫🇷

Toulouse, France

Institut Claudius regaud IUCT Oncopole
🇫🇷Toulouse, France

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.